<DOC>
	<DOCNO>NCT01430585</DOCNO>
	<brief_summary>PF-04691502 inhibitor PI3K mTOR kinase . Published data support hypothesis PI3K/mTOR antagonist combination letrozole might mitigate intrinsic acquire resistance hormonal therapy restore hormone sensitivity high risk ( high Ki-67 ) patient population hormone-sensitive breast cancer . In addition , Ki-67 , marker cellular proliferation , could use select patient benefit treatment PI3K-pathway inhibitor .</brief_summary>
	<brief_title>Pre-Operative Study PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer</brief_title>
	<detailed_description>The study prematurely discontinue 09Oct2012 due tolerability finding 2 clinical study test PF-04691502 prompt Sponsor re-evaluate strategic goal program . In study B1271003 unexpected frequency severe skin toxicity observe study B1271004 5 case drug induce pneumonitis report .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Phase 1 Postmenopausal woman diagnosis breast cancer , metastatic disease locally advanced disease / Estrogen Receptor positive HER2 negative / candidate receive Letrozole Phase 2 Postmenopausal woman newly diagnose primary breast cancer / Estrogen Receptor positive HER2 negative / Ki67 level &gt; 10 % positive cell Phase 1 &amp; 2 Glucose control , adequate bone marrow , liver , renal , cardiac function Inflammatory carcinoma / Prior therapy agent active PI3K and/or mTOR / Significant gastrointestinal abnormality , may impair intake , transit absorption study drug / Current anticipate need food drug know inhibitor inducer CYP3A4</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Ki-67</keyword>
	<keyword>postmenopausal early breast cancer</keyword>
	<keyword>ER positive/HER2 negative early breast cancer</keyword>
</DOC>